CPMG Inc

Q3 2022 13F Holdings Report, Stock Holdings

Signature - Title
John E. Bateman - Chief Operating Officer
Location
Dallas
Holdings as of
30 Sep 2022
Value $
$509,850,000
Num holdings
4
Filing time
14 Nov 2022, 15:31:05 UTC
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included PRCT, RETA, TIL, and APEN.
Previous filing
Q2 2022 - 15 Aug 2022
Next filing
Q4 2022 - 14 Feb 2023
SEC
View on sec.gov
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2022 Q3 compared to 2022 Q2 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John E. Bateman Chief Operating Officer Dallas, Texas 14 Nov 2022

This Form 13F includes only the reportable 2,896,901 Class A shares of Reata Pharmaceuticals, Inc. ("Reata") over which CPMG, Inc. ("CPMG") had investment discretion as of September 30, 2022. This Form 13F does not include the 1,692,857 Class B shares of Reata over which CPMG had investment discretion as of September 30, 2022, because such Class B shares were not included in the relevant quarter's Official List of Section 13(f) Securities, and thus should be excluded.